trial
as of 2026-07-01Stratification and Treatment in Early Psychosis Study - ENHANCE
NCTId NCT06778564
at a glance
Phase 3 · Not Yet Recruiting
Enrollment 250 (estimated)
Sponsored by University of Oxford
Primary completion 2028-02
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 3
Status
Not Yet Recruiting
Enrollment
250 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2026-02
Primary completion
2028-02
Eligibility
ALL · 16 Years · 40 Years
Interventions & indications
Sponsors
University of OxfordLead Sponsor
Wellcome TrustCollaborator
Cambridge Cognition LtdCollaborator
Oxford Health NHS Foundation TrustCollaborator
West London NHS TrustCollaborator
Charite University, Berlin, GermanyCollaborator
University of CologneCollaborator
Ludwig-Maximilians - University of MunichCollaborator
The Sheba Fund for Health Services and ResearchCollaborator
Shalvata Mental Health CenterCollaborator
Geha Mental Health CenterCollaborator
Amsterdam University Medical CenterCollaborator
Hospital General Universitario Gregorio MarañonCollaborator
National and Kapodistrian University of AthensCollaborator
Medical University of ViennaCollaborator
Hospitales Universitarios Virgen del RocíoCollaborator
University of Campania Luigi VanvitelliCollaborator
Psychiatric University Hospital, ZurichCollaborator
Investigators
1
Philip McGuire, MD, PhD, ProfPrincipal Investigator
Sites
17 total
Vienna, AustriaAugsburg, GermanyBerlin, GermanyCologne, GermanyMunich, GermanyAthens, GreeceHod HaSharon, IsraelPetah Tikva, IsraelRamat Gan, IsraelNaples, ItalyAmsterdam, NetherlandsMadrid, Spain
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
250
Phase
PHASE3
Primary Completion Date
2028-02
Status
NOT_YET_RECRUITING
relationships
The graph out of here
drug
drug
lead_sponsor
company
collaborator
company
company
indication
investigator